Scopia Capital Management LP Has $103.18 Million Holdings in Horizon Therapeutics PLC (NASDAQ:HZNP)
Scopia Capital Management LP lowered its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 47.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,288,487 shares of the biopharmaceutical company’s stock after selling 3,870,697 shares during the quarter. Horizon Therapeutics accounts for 4.6% of Scopia Capital Management LP’s investment portfolio, making the stock its 7th largest holding. Scopia Capital Management LP’s holdings in Horizon Therapeutics were worth $103,181,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also made changes to their positions in the company. Manchester Capital Management LLC bought a new position in Horizon Therapeutics in the 1st quarter valued at $41,000. New York State Teachers Retirement System bought a new position in Horizon Therapeutics in the 2nd quarter valued at $55,000. Steward Partners Investment Advisory LLC bought a new position in Horizon Therapeutics in the 2nd quarter valued at $76,000. FNY Investment Advisers LLC bought a new position in Horizon Therapeutics in the 2nd quarter valued at $80,000. Finally, Tower Research Capital LLC TRC grew its stake in Horizon Therapeutics by 384.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,689 shares during the period. Hedge funds and other institutional investors own 86.28% of the company’s stock.
In other Horizon Therapeutics news, Director James Samuel Shannon sold 15,500 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $26.59, for a total value of $412,145.00. Following the sale, the director now owns 15,500 shares of the company’s stock, valued at approximately $412,145. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Paul W. Hoelscher sold 1,359 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $28.00, for a total value of $38,052.00. Following the completion of the sale, the chief financial officer now directly owns 159,310 shares in the company, valued at approximately $4,460,680. The disclosure for this sale can be found here. Insiders have sold a total of 268,616 shares of company stock worth $7,361,526 in the last three months. 4.10% of the stock is currently owned by insiders.
HZNP traded up $0.62 during trading on Friday, reaching $27.12. 75,255 shares of the company were exchanged, compared to its average volume of 899,125. The company’s 50-day moving average is $26.63 and its two-hundred day moving average is $25.71. The company has a market cap of $4.94 billion, a price-to-earnings ratio of 14.96, a P/E/G ratio of 1.56 and a beta of 0.77. The company has a quick ratio of 2.12, a current ratio of 2.20 and a debt-to-equity ratio of 0.90. Horizon Therapeutics PLC has a 12-month low of $16.56 and a 12-month high of $29.44.
Horizon Therapeutics (NASDAQ:HZNP) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.14. The business had revenue of $320.60 million for the quarter, compared to analysts’ expectations of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.48 EPS. Equities analysts forecast that Horizon Therapeutics PLC will post 1.6 earnings per share for the current year.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: Trading based on a resistance level
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.